ReCode Therapeutics’ $120 Million Series B Financing

Wilson Sonsini Goodrich & Rosati represented ReCode Therapeutics in the transaction.

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of messenger RNA (mRNA) and gene correction therapeutics, announced an additional $120 million in Series B financing, co-led by new investors, Leaps by Bayer, the impact investment unit of Bayer AG, AyurMaya, an affiliate of Matrix Capital Management, and with participation from Amgen Ventures. Notably, with the additional $120 million in new financing, ReCode Therapeutics has secured a total of $200 million in Series B funding.

The new investment will expand and diversify ReCode Therapeutics’ platform and pipeline to include mRNA and gene correction therapeutics for lung, liver and central nervous system diseases.

The Wilson Sonsini team that led the transaction included: Ken Clark (Picture), Michael Coke, Christina Poulsen, Eric Abram, Jacie Valentine, Jennifer Gu, Vern Norviel, Ali Alemozafar, Uale Taotafa, Vishakha Negi and Lowell Segal.

Involved fees earner: Eric Abram – Wilson Sonsini Goodrich & Rosati; Ali Alemozafar – Wilson Sonsini Goodrich & Rosati; Kenneth Clark – Wilson Sonsini Goodrich & Rosati; Michael Coke – Wilson Sonsini Goodrich & Rosati; Vishakha Negi – Wilson Sonsini Goodrich & Rosati; Vern Norviel – Wilson Sonsini Goodrich & Rosati; Christina Poulsen – Wilson Sonsini Goodrich & Rosati; Lowell Segal – Wilson Sonsini Goodrich & Rosati; Uale Taotafa – Wilson Sonsini Goodrich & Rosati; Jacie Valentine – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: ReCode Therapeutics;

Martina Bellini

Author: Martina Bellini